Last reviewed · How we verify
Placebo in combination with Epirubicin
Placebo has no pharmacological mechanism; this is a control arm in a clinical trial comparing epirubicin efficacy.
Placebo has no pharmacological mechanism; this is a control arm in a clinical trial comparing epirubicin efficacy. Used for Cancer indication under investigation in phase 3 trial (specific indication not publicly detailed).
At a glance
| Generic name | Placebo in combination with Epirubicin |
|---|---|
| Sponsor | Jiangsu Yahong Meditech Co., Ltd aka Asieris |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
In this phase 3 trial, placebo serves as the inactive control comparator to epirubicin, an anthracycline chemotherapy agent. Epirubicin works by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and cell death in rapidly dividing cancer cells. The placebo arm allows assessment of epirubicin's true clinical benefit over no active treatment.
Approved indications
- Cancer indication under investigation in phase 3 trial (specific indication not publicly detailed)
Common side effects
Key clinical trials
- Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer (PHASE2)
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (PHASE3)
- Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) (PHASE3)
- A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (PHASE1)
- Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (PHASE3)
- Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients (PHASE3)
- A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma (PHASE3)
- Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: